Gene Therapy Cures Leukaemia with Caution
BE-CAR7 uses base editing to make three precise changes to donor T-cells: disabling targeting, removing CD7, and adding chemotherapy resistance.
Nine patients achieved deep remission, enabling bone-marrow transplant, and seven remain disease-free between three months and three years after treatment.
The Great Ormond Street Hospital Charity agreed to support treatment for 10 more patients.
Clinicians caution that treating requires dismantling the immune system, leaving patients vulnerable to infections, and in two cases cancer lost its CD7 marker and rebounded, requiring further study.
1 month ago